Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Mar 13  •  04:00PM ET
4.78
Dollar change
-0.04
Percentage change
-0.83
%
IndexRUT P/E23.37 EPS (ttm)0.20 Insider Own34.01% Shs Outstand79.71M Perf Week-5.53%
Market Cap382.79M Forward P/E13.86 EPS next Y0.34 Insider Trans0.02% Shs Float52.85M Perf Month-6.46%
Enterprise Value320.82M PEG0.37 EPS next Q0.07 Inst Own40.30% Short Float12.22% Perf Quarter-27.36%
Income17.38M P/S2.96 EPS this Y35.00% Inst Trans0.91% Short Ratio5.68 Perf Half Y-50.31%
Sales129.42M P/B4.98 EPS next Y27.78% ROA19.90% Short Interest6.46M Perf YTD-24.84%
Book/sh0.96 P/C5.91 EPS next 5Y37.06% ROE28.35% 52W High14.69 -67.46% Perf Year-38.08%
Cash/sh0.81 P/FCF29.13 EPS past 3/5Y- - ROIC22.19% 52W Low4.72 1.16% Perf 3Y198.75%
Dividend Est.- EV/EBITDA20.37 Sales past 3/5Y21.56% 16.91% Gross Margin64.28% Volatility6.15% 5.74% Perf 5Y-59.32%
Dividend TTM- EV/Sales2.48 EPS Y/Y TTM97.93% Oper. Margin11.05% ATR (14)0.30 Perf 10Y8.39%
Dividend Ex-Date- Quick Ratio3.83 Sales Y/Y TTM29.95% Profit Margin13.43% RSI (14)36.32 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio4.86 EPS Q/Q-44.37% SMA20-5.03% Beta2.22 Target Price13.60
Payout0.00% Debt/Eq0.04 Sales Q/Q16.19% SMA50-14.96% Rel Volume1.06 Prev Close4.82
Employees117 LT Debt/Eq0.02 EarningsMar 04 AMC SMA200-42.62% Avg Volume1.14M Price4.78
IPOJun 24, 2008 Option/ShortYes / Yes EPS/Sales Surpr.127.27% 6.74% Trades Volume1,199,955 Change-0.83%
Date Action Analyst Rating Change Price Target Change
May-27-25Initiated Canaccord Genuity Buy $13
Aug-16-22Downgrade Oppenheimer Outperform → Perform
Aug-11-22Downgrade B. Riley Securities Buy → Neutral $6 → $2.40
Mar-08-22Initiated ROTH Capital Buy $7
Oct-16-19Initiated Oppenheimer Outperform $6
Feb-14-19Initiated B. Riley FBR Buy $7
Nov-27-17Resumed H.C. Wainwright Buy $6 → $8
Sep-25-17Initiated Ladenburg Thalmann Buy $7
Jan-03-17Initiated Rodman & Renshaw Buy $6
Mar-10-26 08:32AM
Mar-05-26 08:30AM
03:56AM
12:03AM
Mar-04-26 05:35PM
04:20PM Loading…
04:20PM
04:06PM
04:02PM
Mar-03-26 09:00AM
Feb-26-26 07:02AM
Feb-25-26 08:32AM
Feb-09-26 08:34AM
Feb-06-26 08:32AM
Feb-02-26 08:16PM
Jan-15-26 08:34AM
08:32AM Loading…
Dec-22-25 08:32AM
Nov-13-25 08:32AM
Nov-12-25 07:52PM
Nov-06-25 08:07AM
Nov-05-25 12:03AM
Nov-04-25 06:00PM
04:58PM
04:02PM
Nov-03-25 07:56AM
Oct-29-25 10:00AM
Oct-28-25 10:00AM
Oct-21-25 08:32AM
Oct-06-25 08:32AM
Oct-01-25 08:32AM
Sep-16-25 08:32AM
05:55PM Loading…
Aug-06-25 05:55PM
04:52PM
04:02PM
Aug-05-25 10:04AM
Aug-04-25 08:32AM
Jul-23-25 08:34AM
Jul-15-25 07:50AM
Jul-14-25 08:32AM
Jul-09-25 09:28AM
Jul-08-25 08:32AM
Jun-20-25 08:32AM
Jun-11-25 08:31AM
Jun-09-25 08:32AM
Jun-04-25 08:32AM
May-08-25 03:26AM
May-07-25 06:00PM
04:02PM
May-05-25 08:32AM
Apr-29-25 08:32AM
Apr-28-25 08:34AM
Apr-07-25 10:32PM
Mar-20-25 08:34AM
Mar-19-25 08:34AM
Mar-13-25 08:34AM
Mar-11-25 04:04PM
Mar-05-25 11:11AM
02:10AM
Mar-04-25 05:15PM
04:13PM
04:02PM
Mar-03-25 07:14AM
Feb-25-25 04:07PM
Jan-06-25 08:32AM
Dec-03-24 08:34AM
Nov-22-24 09:15AM
Nov-14-24 08:32AM
Nov-08-24 12:00PM
Nov-07-24 08:32AM
Nov-05-24 09:15AM
Nov-01-24 11:02AM
Oct-31-24 05:15PM
04:09PM
04:04PM
Oct-30-24 09:20AM
Oct-28-24 08:32AM
Oct-24-24 08:32AM
Oct-23-24 08:34AM
Oct-18-24 09:40AM
Oct-15-24 08:32AM
Oct-09-24 05:18PM
Sep-26-24 04:12PM
09:40AM
Sep-20-24 08:32AM
Sep-10-24 08:32AM
Sep-09-24 08:34AM
Aug-23-24 08:34AM
Aug-19-24 08:32AM
Aug-07-24 06:25PM
05:25PM
04:04PM
Aug-05-24 08:32AM
Jul-24-24 08:34AM
Jul-23-24 08:32AM
Jul-22-24 08:34AM
Jul-16-24 08:34AM
Jul-01-24 08:32AM
Jun-24-24 08:32AM
Jun-13-24 08:32AM
Jun-10-24 09:45AM
Jun-07-24 08:34AM
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pamir OzanChief Financial OfficerNov 14 '25Buy6.814,46530,4067,372Nov 17 08:23 AM
Pamir OzanChief Financial OfficerNov 14 '25Buy6.852,22015,2102,220Nov 17 08:23 AM
Fried Robert NChief Executive OfficerApr 09 '25Option Exercise3.3066,667220,0011,038,981Apr 09 07:52 PM